Harnessing the microbiome to treat skin disease.
Developing novel therapeutics to treat adverse skin conditions
A clinical stage medical dermatology company that leverages its extensive knowledge of proteomics, genetic engineering and the skin microbiome to create and develop novel products for the treatment of skin conditions and diseases.
Broad product opportunities for developing novel antimicrobials and other therapeutics
The Company’s technology platform offers multiple product opportunities in three areas: (1) direct application of commensal bacteria; (2) pharmaceuticals based on the delivery of biotherapeutic proteins to the skin via proprietary bacteria strains; and (3) discovery and development of novel bioactive compounds — e.g., antimicrobials and other therapeutics based on the metabolic products of commensal skin bacteria. Azitra’s lead programs are focused on cancer therapy-associated rashes (CTAR), orphan skin diseases including Netherton syndrome, eczema (atopic dermatitis) and ichthyosis vulgaris.Learn more
The skin microbiome plays a crucial role in human health and dermatologyLearn more
Product pipeline includes four Live Biotherapeutic Product (LBP) candidates
Azitra is focused on making safe, effective, and easy-to-use medical dermatology products. The Company’s product pipeline includes four LBP product candidates in development, including one in the clinic for cancer therapy-associated rashes.
Azitra has changed all product name designations from "AZT" to "ATR".